A tumor of pure lepidic component is now considered adenocarcinoma-in-situ [3], so the fact that KRAS mutations were identified only in the minority invasive acinar component and not in the lepidic component suggests an evolutionary event in this patient. The gene discussed is KRAS; the disease is neoplasm.